In ALK-rearranged NSCLC, a phase II trial demonstrated that detection of ALK translocation in plasma or tissue after TKI failure predicted better responses to lorlatinib, an ALK-TKI inhibitor, while its absence suggested off-target resistance mechanisms [134]. Here, ALK is linked to non-small cell lung carcinoma.